The Qdenga Vaccine: India's New Weapon Against Dengue and the Policy Hurdles Ahead

What prompted the approval of Qdenga in India?

The approval of Qdenga by the Central Drugs Standard Control Organisation (CDSCO) in July 2026 is a direct response to India's escalating dengue crisis. In recent years, the country has witnessed severe dengue outbreaks, with the disease no longer confined to dense urban centres. The Aedes mosquitoes that transmit the virus are now prevalent in semi-urban and rural districts. In these areas, conventional vector control measures under the National Vector Borne Disease Control Programme (NVBDCP), such as fogging and preventing water stagnation, are more difficult to sustain. This geographic expansion, coupled with improved disease surveillance, has highlighted the limitations of existing prevention strategies. The vaccine's approval also follows its successful licensing in over 40 other countries and a critical prequalification from the World Health Organization (WHO), which serves as a global stamp of approval on its safety and manufacturing standards.

How does Qdenga work and differ from past vaccines?

Qdenga is a live-attenuated vaccine built on a DENV-2 backbone, which provides the genetic 'instructions' to produce immune responses against all four dengue serotypes. Its key distinction lies in its design to circumvent the primary safety concern that plagued the first-generation vaccine, Dengvaxia. The 2017 Dengvaxia controversy in the Philippines arose because it was found to increase the risk of severe disease in individuals who had never been exposed to dengue (seronegative). Consequently, its use was restricted to those with a confirmed prior infection.

In contrast, the design of Qdenga, developed by the Japan-based pharmaceutical company Takeda, allows it to be administered without prior screening for dengue infection. This feature presents a significant logistical advantage for mass immunisation campaigns, as it eliminates the need for costly and time-consuming serological testing before vaccination. The vaccine is administered in a two-dose schedule, with the doses given three months apart.